| Metric | Value (₹ Cr) | vs Q3 FY26 |
|---|---|---|
| Revenue | 265.62 | 2.3% |
| Total Income | 277.18 | 5.4% |
| Expenditure | 240.87 | 6.3% |
| PBT | 36.31 | 0.1% |
| Net Profit | 30.37 | 5.8% |
| OPM | 20.24% | 3.19pp |
| NPM | 10.96% | 1.30pp |
| EPS | 3.03 | 11.7% |
Nephrocare Health FY26 Revenue Up 32.2% to ₹998.8 Cr
19 May 2026 · 19 May, 6:52 pm
Summary
Nephrocare Health Services Limited, operating under the brand NephroPlus, reported robust financial results for the fourth quarter and full year ended March 31, 2026. For FY26, revenue increased by 32.2% year-on-year to ₹998.8 crore, with Adjusted EBITDA growing 37.6% to ₹238.1 crore, leading to a 100 bps improvement in Adjusted EBITDA Margin to 23.8%. Adjusted PAT saw a significant jump of 74.6% to ₹128.3 crore for the full year. The growth was primarily driven by a 16.6% increase in treatment volumes and an increased contribution from higher-priced international markets. Management emphasized the scalability of their operating model, focus on clinical outcomes, operational efficiency, and digital innovation, including the Reformmed.AI application, to create sustained value for stakeholders.
Key Highlights
- 1
Nephrocare Health Services Limited reported a strong financial performance for FY26, with revenue growing by 32.2% year-on-year to ₹998.8 crore.
- 2
The fourth quarter of FY26 also saw robust revenue growth of 21.2% year-on-year, reaching ₹265.6 crore.
- 3
Adjusted EBITDA for FY26 increased by 37.6% year-on-year to ₹238.1 crore, while the Adjusted EBITDA Margin improved by 100 basis points to 23.8%.
- 4
Adjusted Profit After Tax (PAT) for the full year FY26 surged by 74.6% to ₹128.3 crore, with the Adjusted PAT Margin expanding by 310 basis points to 12.8%.
- 5
Treatment volumes for FY26 grew by 16.6% year-on-year to 38,44,658, demonstrating strong demand for dialysis care.
- 6
The company's international revenue contribution significantly increased from 31.8% in FY25 to 41.8% in FY26, leading to an uplift in revenue per treatment.
- 7
Return on Capital Employed (Pre-Tax) improved by 290 basis points, reaching 22.8% for FY26 compared to 19.9% in FY25.
Management Comments
Mr. Vikram Vuppala
Across the World, Diabetes and Hypertension disease burdens are increasing significantly. These two diseases are key risk factors for developing Chronic Kidney Disease (CKD). Over a period of time, if not managed properly, CKD patients develop Kidney failure at which point they require Dialysis or a Transplant in order to survive. Prevention of CKD is as important as delivering quality dialysis services to the patients who already have kidney failure. As access to dialysis is increasing across India, other emerging markets and the rest of the World, NephroPlus is positioned to scale well over the next several years. The efficiency engine we have built over the last 16 years serves us well to deliver high quality efficient care across several countries. Focus on excellent clinical outcomes while improving operational efficiency remains the key. Along with focus on scale, we are working hard on digital innovation to transform the way we run operations across our dialysis network. Our Reformmed.AI application is the first comprehensive dialysis operations platform that has already been implemented across 50+ Clinics in our network and is showing great results. Overall, our focus on patient centricity, clinical and operational efficiency, and digital innovation will enable us to sustainably create value for all our stakeholders.
Mr Rohit Singh
FY26 was an important year for NephroPlus as we transitioned into a publicly listed company while delivering strong operating and financial performance. Revenue grew 32.2% to Rs. 998.8 crore, Adjusted EBITDA increased 37.6% to Rs. 238.1 crore, while treatments grew 16.6%, reflecting strong demand for high-quality dialysis care and the strength of our execution capabilities. During the year, we continued to strengthen our leadership position in India, selectively expand internationally, and invest in clinical quality, technology, operational excellence and guest experience — key differentiators for NephroPlus. FY26 reinforced the scalability of our operating model across India and international markets. As we enter FY27, we remain focused on deepening our India presence, scaling our international bus
Informational and educational content only. Not investment advice.